Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, multi centre, Italian, retrospective, real World evidence cohort study describing one and two year Annualized Relapse Rate (ARR) and proportion of patients with No Evidene of Disease Activity (NEDA-3) in patients treated with Fingolimod

Trial Profile

An observational, multi centre, Italian, retrospective, real World evidence cohort study describing one and two year Annualized Relapse Rate (ARR) and proportion of patients with No Evidene of Disease Activity (NEDA-3) in patients treated with Fingolimod

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms GENIUS
  • Most Recent Events

    • 14 Nov 2018 Preliminary results (n=391) assessing Annualized Relapse rate (ARR) and the proportion of patients with No Evidence of Disease Activity (NEDA-3) after 1 and 2 years of treatment, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 24 May 2018 New trial record
    • 23 May 2018 Preliminary results (n=391) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top